Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Posted by on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

Read More

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Posted by on May 31, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination.  This study concluded that these patients should not be excluded from COVID-19 vaccination.  Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Posted by on Dec 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...

Read More

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Dec 5, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the health-related quality of life (HR-QoL) outcomes between pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab improved the HR-QoL outcomes compared to BV in these patients. Some...

Read More

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.   Some background...

Read More

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL).  This study concluded that this treatment combination was safe and effective in these patients.   Some background HL is a common cancer...

Read More